D S Wald

Summary

Publications

  1. ncbi request reprint Randomized trial of folic acid supplementation and serum homocysteine levels
    D S Wald
    Department of Cardiology, St Richard s Hospital, Spitalfield Lane, Chichester PO19 4SE, West Sussex, England
    Arch Intern Med 161:695-700. 2001
  2. ncbi request reprint Mortality from hypertrophic cardiomyopathy in England and Wales: clinical and screening implications
    David S Wald
    Department of Cardiology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
    Int J Cardiol 97:479-84. 2004
  3. ncbi request reprint The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening
    David S Wald
    Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1 M 6BQ, UK
    Eur J Cardiovasc Prev Rehabil 11:250-3. 2004
  4. ncbi request reprint Serum homocysteine and the severity of coronary artery disease
    David S Wald
    Department of Cardiology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
    Thromb Res 111:55-7. 2003
  5. pmc Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
    David S Wald
    Department of Cardiology, Southampton General Hospital, Southampton SO16 6YD
    BMJ 325:1202. 2002
  6. ncbi request reprint Quantifying the effect of folic acid
    N J Wald
    Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts, Charterhouse Square, London, UK
    Lancet 358:2069-73. 2001
  7. pmc Folate and risk of cardiovascular disease. Study results were misinterpreted
    David S Wald
    BMJ 326:1035; author reply 1035. 2003
  8. ncbi request reprint Vitamin supplementation and risk of stroke
    David S Wald
    JAMA 291:2191; author reply 2191-2. 2004
  9. pmc Hypertrophic cardiomyopathy. Sudden death is rare in young people with hypertrophic cardiomyopathy
    David S Wald
    BMJ 333:96-7; author reply 97. 2006
  10. pmc Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence
    David S Wald
    Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London, Queen Mary s School of Medicine and Dentistry, London EC1M 6BQ
    BMJ 333:1114-7. 2006

Detail Information

Publications13

  1. ncbi request reprint Randomized trial of folic acid supplementation and serum homocysteine levels
    D S Wald
    Department of Cardiology, St Richard s Hospital, Spitalfield Lane, Chichester PO19 4SE, West Sussex, England
    Arch Intern Med 161:695-700. 2001
    ..Homocysteine reduction is known to be maximal at a folic acid dosage of 1 mg/d, but the effect of lower doses (relevant to food fortification) is unclear...
  2. ncbi request reprint Mortality from hypertrophic cardiomyopathy in England and Wales: clinical and screening implications
    David S Wald
    Department of Cardiology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
    Int J Cardiol 97:479-84. 2004
    ....
  3. ncbi request reprint The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening
    David S Wald
    Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1 M 6BQ, UK
    Eur J Cardiovasc Prev Rehabil 11:250-3. 2004
    ..It is uncertain whether treatment is best directed at those with high homocysteine or those at high risk irrespective of initial homocysteine...
  4. ncbi request reprint Serum homocysteine and the severity of coronary artery disease
    David S Wald
    Department of Cardiology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
    Thromb Res 111:55-7. 2003
  5. pmc Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
    David S Wald
    Department of Cardiology, Southampton General Hospital, Southampton SO16 6YD
    BMJ 325:1202. 2002
    ....
  6. ncbi request reprint Quantifying the effect of folic acid
    N J Wald
    Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts, Charterhouse Square, London, UK
    Lancet 358:2069-73. 2001
    ..Folic acid is known to prevent neural-tube defects (NTDs) but the size of the effect for a given dose is unclear. We aimed to quantify such an effect...
  7. pmc Folate and risk of cardiovascular disease. Study results were misinterpreted
    David S Wald
    BMJ 326:1035; author reply 1035. 2003
  8. ncbi request reprint Vitamin supplementation and risk of stroke
    David S Wald
    JAMA 291:2191; author reply 2191-2. 2004
  9. pmc Hypertrophic cardiomyopathy. Sudden death is rare in young people with hypertrophic cardiomyopathy
    David S Wald
    BMJ 333:96-7; author reply 97. 2006
  10. pmc Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence
    David S Wald
    Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London, Queen Mary s School of Medicine and Dentistry, London EC1M 6BQ
    BMJ 333:1114-7. 2006
  11. ncbi request reprint Long-term continuation on cardiovascular drug treatment in patients with coronary heart disease
    David S Wald
    Wolfson Institute of Preventive Medicine, London, England
    Ann Pharmacother 41:1644-7. 2007
    ..Combination therapy to reduce risk factors is effective in preventing recurrent cardiovascular disease events in patients with coronary heart disease (CHD), but medications need to be continued indefinitely to maximize the benefits...
  12. ncbi request reprint The future of coronary heart disease prevention
    David S Wald
    Institute of Preventive Medicine, and London Chest Hospital Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London
    Clin Med 7:392-6. 2007
  13. doi request reprint Meta-analysis audit trail
    Nicholas J Wald
    Lancet 371:558. 2008